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Abstract
Background Mutation of the Duchenne muscular dystrophy (DMD) gene causes Duchenne and Becker muscular dystrophy,
degenerative neuromuscular disorders that primarily affect voluntary muscles. However, increasing evidence implicatesDMD in
the development of all major cancer types.DMD is a large gene with 79 exons that codes for the essential muscle protein dystrophin.
Alternative promotor usage drives the production of several additional dystrophin protein products with roles that extend beyond
skeletal muscle. The importance and function(s) of these gene products outside of muscle are not well understood.
Conclusions We highlight a clear role for DMD in the pathogenesis of several cancers, including sarcomas, leukaemia’s,
lymphomas, nervous system tumours, melanomas and various carcinomas. We note that the normal balance of DMD gene
products is often disrupted in cancer. The short dystrophin protein Dp71 is, for example, typically maintained in cancer whilst
the full-length Dp427 gene product, a likely tumour suppressor, is frequently inactivated in cancer due to a recurrent loss of 5’
exons. Therefore, the ratio of short and long gene products may be important in tumorigenesis. In this review, we summarise the
tumours in which DMD is implicated and provide a hypothesis for possible mechanisms of tumorigenesis, although the question
of cause or effect may remain. We hope to stimulate further study into the potential role ofDMD gene products in cancer and the
development of novel therapeutics that target DMD.
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1 Introduction
The Duchenne muscular dystrophy gene (DMD) is best
known for its role in the disease of the same name [1]. DMD
encodes dystrophin protein (Dp) products which are named
based on their length in kDa. The major, and full-length, prod-
uct is the 427 kDa dystrophin protein (Dp427) predominantly
expressed in skeletal muscle [1]. Dp427 is essential for main-
taining muscle integrity through connecting the actin cyto-
skeleton to the extracellular matrix. It achieves this through
association with various proteins to form a transmembrane
scaffolding complex called the dystrophin-associated protein
complex (DAPC). The loss of dystrophin, through out-of-
frame DMD gene mutation, in Duchenne patients is responsi-
ble for severe muscle degeneration and premature death [1].
TheDMD gene consists of 79 exons. It is one of the largest
human genes and is located on the short arm of the X chro-
mosome at position Xp21.2-p21.1. Seven independent tissue-
specific promoters, as well as an alternative polyadenylation
site, drive the transcription of multiple dystrophin protein var-
iants (Fig. 1) [1]. Full-length dystrophin contains several func-
tional domains: an N-terminal actin-binding domain, a central
rod domain, a WW domain, a cysteine-rich domain and a C-
terminal domain (Fig. 1). The cysteine-rich domain contains
EF hand and ZZ domains that contribute to the stability of the
WW domain and the interaction of dystrophin with dystrogly-
can, a member of the DAPC. The shorter dystrophin protein
variants do not contain the N-terminal actin-binding domain,
but instead have a shorter rod domain. Dp71 and Dp40 addi-
tionally lack the rod domain and part of the WW domain
(Fig. 1). Many DMD gene products are alternatively spliced
to produce multiple splice isoforms. Outside skeletal muscle,
the most predominant and ubiquitous DMD gene product is
Dp71, of which at least 14 splice isoforms have been identi-
fied [2]. These have been organised into groups, with the most
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common being Dp71d group isoforms that contain exon 78
and Dp71f group isoforms that do not contain exon 78. The
grouping denotes alternative C-termini [2]. Dp71 exhibits a
large functional diversity and its loss in the brain of Duchenne
patients is thought to be responsible for cognitive and behav-
ioural comorbidities [2].
DMD is located within the low-expressing FRAXC com-
mon fragile site (CFS, large regions of profound genomic
instability) [3]. Genes within CFSs are frequently deleted
and/or altered in cancer. Most of these sites span extremely
large genes, some of which are known tumour suppressors.
Their inactivation in different cancers is deemed non-random
[4]. A common basis may underlie the frequent occurrence of
CFS/DMD rearrangements in germ cells of DMD patients and
similar alterations found in cancer cells [5].
Although case reports of cancer in Duchenne patients are
rare and confined to round cell tumours to date [6–14]
(Table 1), a growing and intriguing collection of evidence
implicates the DMD gene and/or its protein products in
tumourigenesis. Between 2007 and 2011 several studies have
emerged showing that muscular dystrophy mouse models are
prone to develop spontaneous soft tissue sarcomas (STS)
[15–17]. Since then, numerous reports, of increasing frequen-
cy, have characterised DMD gene mutations and/or expres-
sion changes associated with the development, progression
and/or survival of patients with a wide range of cancers in-
cluding sarcomas, carcinomas, melanomas, lymphomas and
leukaemia’s, as well as brain tumours [18–26]. Although a
question of cause or effect remains, it is now clear that a role
for DMD in cancer extends beyond just myogenic or muscu-
loskeletal tumours and that the ratio of Dp427 to Dp71 may
have particular importance. Here, we comprehensively review
the overlooked, but accumulating evidence supporting a role
for the DMD gene and its variants in neoplastic disease.
2 Sarcomas
Given the canonical role of dystrophin in muscle, it is unsur-
prising that a large body of evidence for a role for DMD in
cancer comes from soft tissue sarcomas (STS), and the myo-
genic tumours in particular. We first review current knowl-
edge on the incidence of STS in DMD patients and animal
models before discussing wider evidence implicating DMD
gene alterations in sarcoma patients.
2.1 Evidence from DMD patients and animal models
We are aware of four clinical case reports (Table 1) on the
concomitant occurrence of Duchenne muscular dystrophy
(DMD) and rhabdomyosarcoma (RMS, the most common
STS of childhood) [7–10]. The literature has not yet extended
beyond this to investigate the true incidence and risk of STS in
DMD patients. Reports of spontaneous tumour formation in
muscular dystrophy mouse models, however, have gained
more traction [15–17, 27] and have been reviewed in [28].
Chamberlain et al. were the first to report that older mdx
mice (above 16months of age) are prone to develop RMS-like
tumours of the alveolar type [15]. The mdx mouse is a widely
used non-transgenic DMD mouse model with a naturally oc-
curring mutation (nonsense point mutation [C-to-T transition]
in exon 23) abolishing Dp427 expression. RMS are extremely
rare to non-existent in non-transgenic mice beyond mdx and
are thought to only occur after genetic manipulation of the
Fig. 1 Structure of the DMD
gene. a Schematic diagram
showing the location of the seven
independent promoters within the
DMD gene. b Differential
expression and domain structure
of the different gene products,
including unique first exons.
Dp71 and Dp40 share a common
promoter and first exon, Dp40 is
produced through the use of an
alternative polyadenylation site.
Note that additional splice
isoforms of Dp427p, Dp260,
Dp140 and Dp71 are not shown.
WW: WW domain; Cys: cysteine
rich domain; CT: C-terminal
domain
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mouse genome [15]. Chamberlain et al. postulated that the
increased incidence of RMS among mdx mice is due to the
characteristic lifelong degeneration and regeneration of
myofibres. This results in over-activation and proliferation
of satellite cells and an increased risk of spontaneous muta-
tions affecting the differentiation of their progeny [15]. This is
in contrast to DMD patients, where the incidence of RMS
appears lower, seemingly as a result of a significant drop in
muscle mass and satellite cell numbers and their prema-
ture proliferative senescence [29]. In support of this,
some studies have identified satellite cells as a potential
origin for RMS [30].
Other studies have since confirmed the propensity of ani-
mal models lacking components of the DAPC to develop tu-
mours. For example, dystroglycan abnormalities have been
linked to cancer [16, 31, 32]. Dystrophin complexes with dys-
troglycan and loss of dystrophin is known to affect the
level and localisation of other DAPC components [33].
In line with the results of Chamberlain et al., Fernandez
et al. reported spontaneous development of RMS in 9%
of mdx mice aged to over one-year-old, whilst none of
the 450 similarly aged wild-type mice from their study
developed tumours [16]. Fernandez et al. further characterised
the RMS tumours in mdx mice and found that they are con-
sistent with embryonal RMS (ERMS) rather than alveolar
RMS (ARMS) as per the Chamberlain study [16].
They also found that mdx ERMS tumours showed al-
tered expression patterns and mutations of known equiv-
alent to human RMS-associated genes such as TP53 and
mouse double minute 2 ortholog (MDM2), a negative
regulator of p53 [16].
A tumour suppressor role for dystrophin in mice is support-
ed by another study by Schmidt et al. reporting a much higher
incidence of mixed soft tissue tumours, including ERMS, in
almost 40% of mdx mice [17]. It is unknown if this higher
incidence is due to environmental factors. This study high-
lights the complex heterogeneous nature of STS tumours in
mdx mice, with Chamberlain et al. and Fernandez et al. also
reporting different histological subtypes. Schmidt et al. stud-
ied the incidence and onset of tumours in mdx (C57BL/10
background), mdx3cv (C57BL/6 background and deficient in
C-terminal dystrophin gene products) and novel inbred strains
revealing a strain-independent tumour suppressive role for
dystrophin. However, the age of onset and incidence was
strongly strain-dependent, with the C57BL/10 background
of mdx mice being the most tumour-susceptible [17]. The
additional loss of other muscular dystrophy-associated genes
such as dysferlin and calpain-3 in double-mutant mouse lines
was found to reduce sarcoma latency [17]. Another indepen-
dent study reported RMS in > 90% of dystrophin and dysferlin
double mutant mice [27]. Genomic analysis of solid tumours
from mdx mice revealed genomic instability, DNA damage
and frequent amplification of the Met or Jun oncogenes, loss
of Cdkn2a and Nf1 tumour suppressor genes and recurrent
duplications of chromosomes 8 and 15, with chromosome
15 duplication being the more preferable duplication [17].
Interestingly, such genetic lesions are present before sarcoma
development in aged mdx mice and, importantly, DMD pa-
tient skeletal muscle tissues also display gross genomic insta-
bility [17]. Adding to earlier theories, Schmidt et al. suggested
that the adipocyte and connective tissue proliferation charac-
teristics of DMD may create the required molecular context
Table 1 Reports of concomitant DMD and cancer
Report Tumour type DMD mutation causative
of Duchenne
Age at cancer
diagnosis (years)
Outcome
Johnston et al. [12] Stage III neuroblastoma Unknown 0.75 Alive > 25 months post-surgery
and chemotherapy treatment
Svarch et al. [13] Acute lymphoblastic leukemia Unknown Unknown Unknown
Rossbach et al. [8] Stage IV ARMS Deletion of exons 47–50 4 Alive after biopsy, chemotherapy
and radiation treatment
Korones et al. [14] Stage III Wilms tumour Unknown 3 Alive six months after surgery,
chemotherapy and radiation treatment
Jakab et al. [7] Stage II ERMS Unknown 7 Dead of disease 30 months after diagnosis
Saldanha et al. [9] RMS Unknown 5 Unknown post discharge after surgery
Doddihal and Jalali [6] High risk medulloblastoma Exon 44 deletion 7 Residual disease after surgery and
radiation treatment, alive at
8 months post diagnosis
Büget et al. [10] Massive RMS Unknown 17 Unknown after discharge following
left arm amputation
van den Akker et al. [11] High risk medulloblastoma Point mutation
in exon 32
(c.4483C > T)
9 Alive 30 months post surgery,
chemotherapy and radiation
treatment with no residual
or recurrent disease
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for sarcoma development from multipotent mesenchymal or
muscle-derived stem cells.
A more recent study showed that, in a severe DMD mouse
model, RMS formation and latency was affected by disease
severity and that muscle stem cells from these mice can give
rise to tumour spheres in vitro and RMS tumours in vivo [34].
Taken together, these studies indicate that the degenerative
muscle environment of Duchenne patients (which has been
associated with increased genetic instability in whole muscle)
may promote the development of RMS through increased tis-
sue turnover. This work highlights caution to be taken for the
development of DMD therapeutics that act on the self-renewal
ability of muscle stem cells.
2.2 Evidence from human STS tissues
Outside the context of Duchenne muscular dystrophy, evi-
dence for the involvement of the DMD gene in STS develop-
ment is growing. A seminal study by Wang et al. cemented
Dp427 as a tumour suppressor in myogenic tumours, where
intragenic deletion of the DMD gene is a frequent mechanism
by which they progress to high-grade lethal sarcomas [18].
This added to existing knowledge that the UTRN gene, which
codes for the dystrophin-related protein utrophin, also acts as a
tumour suppressor [35]. Using genome-wide single nucleo-
tide polymorphism (SNP) assays,Wang et al. found intragenic
DMD deletions in 63% of high-grade myogenic cancers, in-
cluding gastrointest inal s t romal tumour (GIST),
leiomyosarcoma (LMS) and RMS. These deletions were not
found in surrounding non-neoplastic tissues suggesting a so-
matic origin, and their frequency was higher in myogenic
tumours compared to non-myogenic sarcomas or non-
sarcoma cancer cell lines [18]. Further exploration using mul-
tiplex ligation-dependent probe amplification (MLPA)-based
copy number assessment for each exon revealed DMD dele-
tions in 43% of high-grade myogenic cancers [18]. These
deletions are typically large, and although they vary between
individuals, they usually begin with exons 1–3 and never ex-
tend past exon 62. As a result, all the deletions abolish Dp427
expression, which was absent or weakly present in 96% of
metastatic GIST, 62% of metastatic LMS and 100% of meta-
static RMS. Dp427 was strongly expressed in normal and
benign counterparts for all tumour types studied.
Interestingly, Wang et al. reported that expression of the
smaller DMD gene product, Dp71, is maintained in cancers
with DMD deletions. Knockdown of Dp71 in DMD-deleted
RMS cells inhibited cell growth, suggesting that Dp71 expres-
sion is a requirement for myogenic tumours [18]. Re-
expressing Dp427 using a miniDMD construct lacking exons
17–48 inhibited migration, invasion and invadopodia forma-
tion in multiple myogenic sarcoma subtypes, lending support
to the hypothesis that depletion of Dp427 promotes the meta-
static potential of myogenic tumours [18]. Indeed, Wang et al.
reported that the sameDMD deletions from onemetastasis can
be seen in all other metastases from the same patient. The
authors suggested that DMD inactivation may be a driving
event in myogenic cancer development and a target for thera-
peutic attack.
Subsequent work on GIST (the most common sarcoma of
the gastrointestinal tract) confirmed an association between
the dysregulation of dystrophin and GIST progression.
Firstly, in a commentary in 2015, Wang and Fletcher [36]
suggested, based on their work that DMD inactivation is a
late-stage event enabling metastatic spread in GIST. GISTs
largely result from constitutively activating mutations in KIT
or PDGFRA receptor tyrosine kinases. Mutations disrupting
the regulation of the cell cycle may serve as subsequent
drivers of tumour progression, resulting in low-risk and
high-risk GIST classifications. DMD inactivation adds a final
step to a model for metastatic spread of myogenic cancers
[36]. Additionally, another group confirmed the presence of
DMD deletions in an Italian GIST series. In this study DMD
deletions were only found in KIT/PDGFRA mutant GISTs
(31% vs. 0% in wild-type), supporting the idea of DMD inac-
tivation as a late event in metastatic progression [37].
Interestingly, the deletions identified in this study also in-
volved the 5’ region with exons 2–7 being recurrently
affected.
More recently, Mauduit et al. analysed 318 sarcomas using
array CGH and confirmed the occurrence ofDMD deletions in
16.5% of all types examined, 16.5% in sarcomas with com-
plex genomic profiles (including LMS), 21.6% in synovial
sarcomas and 14.2% in GISTs. The deletions were associated
with metastatic development and decreases in DMD gene ex-
pression. In line with previous work, these deletions appeared
to be restricted to the 5’ region of DMD and to affect the
expression of the full-length Dp427 gene product. RNA se-
quencing analysis revealed that Dp71 was the onlyDMD gene
product left intact [38]. Mauduit et al. for the first time found,
using metastasis-free survival analysis, that intragenic DMD
deletions are associated with a poorer prognosis, indicating
that DMD deletion is an independent biomarker of metastatic
evolution. Conversely, the authors found that neither Dp427
nor Dp71 expression levels were prognostic for metastatic
progression, suggesting a central role for Dp427 deletion in
this process [38]. Subsequent in vitro studies revealed, how-
ever, that Dp427 downregulation using CRISPR/Cas9 had no
effect on the proliferation, migration or clonogenic properties
of LMS cells [38]. In contrast, Dp71 downregulation using
shRNA in synovial sarcoma and LMS cells that express
Dp71, but not Dp427, did show a diminished proliferation,
an abolished ability to grow as isolated clones and G2/M cell
cycle phase arrest [38]. Dp71d (containing exon 78) plays a
known role in cell division, where it is localised at the mitotic
spindle poles of rat pheochromocytoma PC12 cells and acts
through interaction with lamin B1 and β-dystroglycan [2, 39].
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Inhibition of Dp71 likely induces cell cycle arrest, which may
explain the requirement of Dp71 for tumour progression.
Dp71 is, therefore, an attractive therapeutic target for
Dp427-depleted sarcomas.
Inactivation of tumour suppressor genes through homozy-
gous deletion is common in cancer. Intron retention is another
common mechanism by which tumour suppressor genes may
be inactivated [40]. As such, DMD intron retention cannot be
ruled out as a potential mechanism for Dp427 inactivation in
some cancers. Evidence for this notion came from Niba et al.
who assessed dystrophin expression in the ARMS-derived
cell line CRL-2061. These cells do not contain full-length
dystrophin protein despite the presence of a full and structur-
ally normal DMD gene and full-length mRNA expression. In
this cell line, three retained introns (40, 58 and 70) accumu-
lating in 90% of DMD transcripts are present, which are
thought to abolish dystrophin expression through the intro-
duction of stop codons and, thereby, disruption of the tumour
suppressive role of Dp427 [41]. Dp71was not studied byNiba
et al. who nonetheless suggested that post-transcriptional
DMD modifications should be considered as secondary alter-
ations in cancer. Cancer-specific vulnerabilities can be ex-
posed when a deleted tumour suppressor gene is part of a
family of functionally redundant genes [38, 42]. In the case
ofDMD inactivation in sarcomas, metastatic progression may
be determined by the ratio of Dp427 to Dp71, a suggestion
that warrants further investigation.
3 Tumours of the nervous system
The studies byWang et al. described above indicate thatDMD
deletions are infrequent in non-myogenic tumours, but they
did not fully analyse DMD mRNA expression levels across
other tumour types. Luce et al. investigated DMD expression
levels and genetic alterations in non-myogenic tumours in
pairwise comparisons to normal tissues. They studied 16 tu-
mour types using microarray-based gene expression and
RNAseq datasets from the GEO database and cBioPortal pub-
lic repositories, respectively. The RNAseq data showed that
the median frequency of DMD alterations in non-myogenic
tumours (3.4%) was higher than that in other common tumour
suppressor genes, such as BRCA1 (1.6%), BRCA2 (2.8%) and
PTEN (3%). Several cancers of the nervous system were in-
cluded in this study, revealing that DMD is significantly
overexpressed in ependymoma and astrocytoma, but signifi-
cantly under-expressed in medulloblastoma and non-
significantly under-expressed in glioblastoma [43]. The au-
thors speculated that these findings may be attributed to
Dp71, as it is the predominant DMD product in the brain
and has been shown to play a role in proliferation, invasion
and migration [2, 24, 44]. However, the study did not differ-
entiate the expression of different isoforms and no
immunohistochemistry was performed to correlate the find-
ings to protein expression.
3.1 Neuroblastomas
Other studies have investigated the role of DMD gene dele-
tions in neuroblastomas using patient samples. Gallia et al.
performed whole exome sequencing (WES), whole genome
sequencing (WGS) and SNP array analysis on 14 olfactory
neuroblastoma patient samples and found that somatic DMD
deletions occurred in 86% of the tumours [22]. In line with
DMD deletions in STS, in olfactory neuroblastoma these are
concentrated in the 5’ end of the gene and all but one are
predicted to preserve Dp71 expression. Numerous DMD tran-
scripts were encountered in the neuroblastoma cell line SH-
SY5Y and, as observed in an ARMS cell line described above
[42], DMD transcripts in SH-SY5Y cells showed retention of
part of intron 40, implying that this event may be cancer-
specific and represent another means of DMD dysregulation
in neurological cancers [45].
3.2 Meningiomas
The findings in olfactory neuroblastoma are supported by a
similar study evaluating DMD gene deletions in high grade/
progressive meningioma patient samples [46]. Of the 55 pa-
tients with progressive/high grade tumours evaluated, 17
(32%) either exhibited deletions in the DMD gene or silenced
expression. Somatic DMD deletions were found in 5/24 pa-
tient samples (20.8%), spanning exons 2–30 in three male
patients and the entire gene in two female patients. Further
genome-wide analysis of fragile sites and 40 other large genes
indicated that these do not represent general non-specific ge-
nome instability [46]. Western blotting and immunohisto-
chemistry on patient tissues harbouring DMD deletions con-
firmed a loss or reduction of Dp427 protein expression, and
electron microscopy revealed a reduced density of cytoskele-
ton filaments in tumour cells. Interestingly, compared toDMD
wild-type, patients withDMD alterations showed significantly
shorter progression-free (1.6 years vs. 2.6 years, p = 0.038)
and overall survival (5.1 years vs. median not reached, p =
0.006) times [46]. DMD alterations were also found to be
significantly more common in progressive/high grade menin-
giomas than in grade I and II non-progressive meningiomas.
This suggests that DMD inactivation may be associated with
high grade malignancy in meningioma. Adding to evidence
for a role for DMD in meningioma, Paramasivam et al.
analysed mutation patterns and regulatory networks in menin-
gioma tumour samples and found that DMD was the second
most frequently altered gene (19% of cases) [47]. Of 12 sam-
ples harbouring DMD mutations, 11 had alterations in both
copies of the neurofibromin 2 (NF2) gene, the most common-
ly mutated gene in meningioma, which encodes the tumour
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suppressor protein merlin. Expression analysis of methylation
subgroups showed that DMD expression was higher in sub-
groups with NF2mutations compared to NF2 wild-type cases
[47]. DMD was also found to be one of the most highly up-
regulated genes in NF2 mutant samples. Future functional
work would be useful to identify specific roles of DMD var-
iants in meningioma development.
3.3 Glioblastomas
As part of a study on the selective loss of large CFS genes in
cancer, McAvoy et al. showed thatDMD expression (by qRT-
PCR using primers in the 3’-untranslated region) is reduced in
all brain tumour cell lines tested, as well as in a xenograft
derived from an intracranial model of glioblastoma (GBM)
[3]. A complex picture of DMD, and likely DAPC, disruption
within nervous system tumours is apparent since alterations in
the dystrophin-associated protein α-dystroglycan have also
been reported in human gliomas [48]. The major dystrophin
protein in the brain is Dp71 and it exhibits a large functional
diversity. Evidence supports the presence of functional Dp71-
containing DAPCs in the brain, but the individual components
may vary according to cell type [2]. Of note, Dp71 plays a role
in maintaining blood brain barrier integrity, which is disrupted
in human gliomas as well as in the mdx mouse model [2, 49].
To date, six Dp71 splice isoforms have been identified in the
U251-MG glioblastoma cell line and, as yet, their specific
functions are unclear [50]. There is value to investigating the
effects of individual dystrophin proteins on neurological can-
cers, in addition to overall DMD expression and mutation
analyses. Ruggieri et al. looked specifically at Dp71 in human
GBM, the most aggressive malignant CNS tumour, and me-
ningioma. They found that expression attributed to Dp71d
was increased in a meningioma cell line and decreased in
GBM cell lines and in human GBM biopsy specimen cells
compared with a normal human astrocyte cell line [23].
They also showed that a higher Dp71 expression was associ-
ated with a lower Ki-67 proliferative index in GBM patients,
which may suggest that increased Dp71 expression is associ-
ated with reduced proliferation.
3.4 Summarising DMD dysregulation in nervous
system tumours
Taken together, these results highlight some inconsistencies
when evaluating total DMD expression in cancer, as high
DMD expression may be associated with the progression of
certain cancers whereas low expression may be associated
with the progression of others. As with STS, the ratio of
Dp427 to Dp71 may be a pertinent factor and, thus, differen-
tiating between these isoforms in mRNA and protein expres-
sion studies is important. Furthermore, it is possible that dif-
ferent tumours and/or tissues express a different complement
of Dp71 isoforms which may serve to either supress or prog-
ress tumour development. A fuller understanding of dystro-
phin biology in the brain is required. It has been reported that a
complex DMD neuropsychiatric syndrome arises from the
absence of distal DMD gene products in the brain of
Duchenne patients [2]. This indicates that altered DMD gene
products in the brain can disrupt nervous system function
regardless of cancer. Of note, there is a case report of neuro-
blastoma in DMD [12], as well as two other case reports
describing medulloblastoma in children with DMD
(Table 1). The former described a seven year old boy with a
DMD deletion of exon 44 and the latter a nine year old boy
with a DMD point mutation in exon 32 with anaplastic me-
dulloblastoma [6, 11]. The central location of both of these
mutations in the dystrophin gene suggests that Dp71 is unaf-
fected and that the individuals are not expected to display
severe intellectual disability based on our knowledge of the
genotype to phenotype ratio in DMD [2]. The ratio of Dp427
to Dp71 would presumably, however, be disrupted.
4 Melanomas
Downregulation ofDMD has first been implicated in the path-
ogenesis of malignant melanoma by Kӧrner et al. [21]. Digital
karyotyping and multiplex PCR analysis of cell lines derived
from established metastatic melanomas revealed DMD dele-
tions in the M1 (in-frame deletion of exons 3–29), RPMI-
7951 (in-frame deletion of exons 17–30) and WM-793 (out-
of-frame deletion of exons 42–43) cell lines [21]. These dele-
tions are outside the major hotspot region of exons 45–53 for
DMD mutations in Duchenne muscular dystrophy patients
[51, 52] and appear to be tumour-specific mutational events
[21]. DMD expression analysis of full-length Dp427 variants
in non-cancerous primary melanocytes from three different
donors revealed high expression levels of Dp427m [21].
Conversely, in a panel of 55 melanoma cell lines, Dp427m
expression was found to be very low in 18% of the lines and
absent in 69% of them. In comparison to normal melanocytes,
32/37 melanoma cell lines exhibited a reduced DMD expres-
sion [21]. Additionally, the same melanocytes also expressed
Dp71 and Dp116. Western blot analyses revealed that Dp71
expression was maintained independent of that of Dp427 in
100% of the melanoma cell lines analysed, whereas Dp116
expression was only present in 20% of cell lines negative for
Dp427m. This is akin to STS and nervous system tumours,
where the balance of Dp427 and Dp71 has also been found to
be disrupted.
To further investigate the decreased DMD expression ob-
served in malignant melanoma, DMD RNA was isolated and
cDNA sequenced from 34 melanoma cell lines (25 negative
and nine positive for full-length dystrophin) and three primary
melanomas with low DMD mRNA expression levels [21].
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The sequencing results revealed five known polymorphisms
and six new variants including D214N (MM-232 cell line)
located within the actin-binding domain and G3189E
(WM1205LU cell line) located within the C-terminal ZZ do-
main [21]. These variants are considered to be melanoma-
specific since no new variants were found in cell lines express-
ing Dp427m that may affect dystrophin function. Indeed,
there is evidence for a functional DAPC in melanocytes [21]
and the importance of dystrophin for melanocyte cell function
warrants further investigation.
Knockdown of Dp427m in melanoma cell lines (M7 and
C-32) resulted in reduced spheroid formation and enhanced
migration and invasion capacities [21]. Kӧrner et al. also re-
stored dystrophin expression in cell lines with no detectable
dystrophin protein using a GFP-tagged full-length dystrophin
expression construct. Decreased migration, reduced prolifera-
tion and induction of cellular senescence were observed in the
restored cell lines compared to the respective controls [21].
The latter effect on cellular senescence is a common phenom-
enon after tumour suppressor gene expression restoration, fur-
ther supporting a role for DMD in tumour suppression [53,
54]. The findings of Kӧrner et al. are supported by a bioinfor-
matics study of Luce et al. who reported thatDMD expression
is lower in melanoma tissues in comparison to normal skin
tissues [43].
5 Haematological malignancies
5.1 Lymphomas
Lymphomas and lymphocytic leukaemia’s have both been
linked to aberrant DMD gene expression [43]. Baumforth
et al. showed, using microarray-based analyses (with a DMD
probe set that detects allDMD transcripts) thatDMD is down-
regulated 8-fold in primary Hodgkin’s lymphoma (HL, nodu-
lar sclerosing subtype) tumour tissues compared to germinal
centre B cells [19]. This finding was supported by Luce et al.
who similarly observed downregulation of DMD in lympho-
mas vs. normal centroblasts and centrocytes [43]. The onco-
genic herpesvirus, Epstein-Barr virus (EBV), is present in ap-
proximately half of HL tissues and cells. Baumforth et al.
found that DMD expression is upregulated in EBV-positive
HL tissues and cells compared to non EBV-positive HL tis-
sues and cells (1.66-fold in tissue and 1.64-fold in L591 cells)
[19]. These findings warrant further investigation to explore
the potential oncogenic role of EBV-induced DMD upregula-
tion in lymphomas and whether EBV is associated with dif-
ferential expression of dystrophin in other EBV-associated
malignancies. Interestingly, there have been two reported case
studies of young boys with Hodgkin’s disease and non-
Hodgkin’s lymphoma (a large B-cell lymphoma of the as-
cending colon) associated with Becker muscular dystrophy,
the milder allelic form of DMD caused by in-frame DMD
deletions [55, 56].
5.2 Leukaemia’s
One case report of DMD concomitant with acute lymphoblas-
tic leukaemia has so far been published [13] (Table 1) and
several independent studies using microarray-based gene ex-
pression profiling have highlighted the diagnostic potential for
DMD in B-cell chronic lymphocytic leukaemia (B-CLL)
[57–59]. Nikitin et al. further reported that high DMD expres-
sion across 134 B-CLL patients was associated with a shorter
lymphocyte doubling time and was predictive of a poor pa-
tient survival (median overall survival for patients with high
DMD expression was 90.1 months vs. median not reached for
patients with low DMD expression) [20]. These observations
are in contrast with the trend towards a tumour suppressive
role for DMD in other tumours, although this does appear to
be restricted to Dp427. We note that the primer and probe set
used in this study spans exons 66–68 and will, therefore, de-
tect both Dp71 and Dp427 expression. The increased DMD
expression in B-CLL can, therefore, not be attributed to either
Dp427 or Dp71. The increased expression has, however, been
found to be associated with the mutation status of immuno-
globulin variable region genes (IgVH) (p < 0.0001), which is
considered the strongest long-term predictor of progno-
sis in B-CLL [20]. As with other tumour types, it re-
mains to be seen whether DMD plays a key role in the
pathogenesis of B-CLL or whether its altered expression rep-
resents a secondary event. Interestingly, reduced dystroglycan
expression has previously also been linked to the pathophys-
iology of leukaemia [60].
6 Carcinomas
6.1 Lung adenocarcinomas
Dp71 has been reported by Tan et al. to have an oncogenic
role in lung adenocarcinoma cells using several in vitro func-
tional assays. The authors silenced total Dp71 (albeit, non-
specifically since the target was exon 69 present also in
Dp427) using shRNA in A549 cells and found that the
Dp71-depleted cells grew, migrated and invaded significantly
slower than the empty vector control cells [24]. Cisplatin-
induced apoptosis was also found to be increased in Dp71-
depleted cells via enhanced caspase activity. Furthermore,
in vivo, a xenograft mouse model established with Dp71-
depleted cells showed reduced tumour growth compared to
controls. The tumours expressed lower levels of lamin B1 (a
Dp71-binding partner), matrix metalloproteinase 2 (MMP-2)
and B cell lymphoma 2 (Bcl-2) [24], which the authors linked
to the reduced malignancy in this model.
The Duchenne muscular dystrophy gene and cancer
Subsequently, Luce et al. reported significantly reduced
DMD expression in lung adenocarcinoma and non-small cell
lung carcinoma tissues vs. normal lung tissues using data ob-
tained from the GEO repository with a probe set that detects
all DMD transcripts [43]. Given the findings of Tan et al. and
the evidence from other tumours discussed in this review, it is
possible that the reduced expression observed by Luce et al.
relates to reduced Dp427 expression, but further study is need-
ed to confirm this hypothesis.
6.2 Gastric adenocarcinomas
In contrast to the oncogenic role of Dp71 in lung adenocarci-
nomas as discussed above, a second paper by Tan et al. re-
ported tumour suppressive associations of Dp71 expression in
gastric adenocarcinomas. Reduced Dp71 protein and mRNA
expression levels were found in ~ 70% of primary gastric ad-
enocarcinoma patient tumour tissue samples compared to
matched non-tumour tissues [25]. We note, however, that
the antibody and primers used in this study cannot distinguish
between Dp427 and Dp71, except on Western blots where a
reduction in Dp71 in tumour tissues was evident.
Immunohistochemical analyses also revealed that cancer cell
differentiation and lymph vascular invasion were significantly
associated with Dp71 downregulation. In line with this find-
ing, Kaplan-Meier analysis of patients after surgical resection
revealed that those with a high Dp71 expression exhibited a
significantly favourable overall survival time compared to
those with a low Dp71 expression (56.56% vs. 30.8% 5-year
survival rate, respectively; p < 0.001) providing evidence that
Dp71 may act as a tumour suppressor in gastric adenocarci-
noma [25]. To support this notion, Tan et al. overexpressed
either Dp71d or Dp71f in gastric cancer cells (which also
exhibited diminished Dp71 expression) and observed inhibi-
tion of proliferation in the transfected cells compared to con-
trols. Additionally, co-immunoprecipitation analysis con-
firmed an interaction between Dp71 and lamin B1 in normal
human gastric epithelial cells, supporting previous findings
and suggesting a critical role for Dp71 in cell division and a
potential importance of the Dp71-lamin B complex in tumour
suppression [25, 39].
6.3 Carcinomas of the head and neck
Nasopharyngeal carcinoma (NPC) originates from epithelial
cells within the nasopharynx. Its incidence is highest among
males and its occurrence is particularly frequent in China. An
X chromosome-wide association study for SNPs in 1590
Chinese NPC patients and 994 controls revealed an associa-
tion within the DMD gene (intronic SNP rs5927056, p =
1.49 × 10− 5), which was validated in Taiwanese and
Malaysian replication cohorts [26]. Combination analyses re-
vealed a consistent association in males and showed that the
DMD SNP rs5927056 is associated with a reduced risk of
NPC (odds ratio: 0.85, p = 9.44 × 10− 5) [26]. Additionally,
NPC risk association with X chromosome SNPs was found
to be decreased by 8.3% after excluding rs5927056, suggest-
ing a strong effect of this locus on NPC susceptibility.
Additional RNAseq and qRT-PCR analyses of oropharyn-
geal squamous cell carcinoma (OPSCC) tissues revealed
DMD as one of a number of large CFS genes to be signifi-
cantly downregulated in tumour tissues [61]. Decreased ex-
pression of a select group of six genes, including DMD, was
found to be associated with an increased recurrence of
OPSCC [62]. The prognostic utility of DMD alone was not
studied.
6.4 DMD across other carcinomas
Next to the carcinomas discussed above, Luce et al. reported
downregulated DMD expression in primary and metastatic
prostate cancers, pancreatic ductal adenocarcinomas and co-
lon and breast cancers. In case of prostate cancer, the expres-
sion of DMD decreased further when the cells became meta-
static. This observation was consistent with that in melano-
mas, which showed a decreased expression compared to that
in benign nevi, which in turn showed a decreased expression
when compared to normal skin tissue. Interestingly, in spo-
radic breast cancer, the median frequency of DMD alterations
(3.95%) was higher than those ofBRCA1 (1.95%) and BRCA2
(3.4%) [43]. Additional survival analyses revealed that in
breast and uterine cancer, patients with DMD alterations ex-
hibited significantly poorer survival rates compared to wild-
type patients [43]. Overall, with the exception of renal cell
carcinoma in which DMD is upregulated [43], there is a trend
for DMD downregulation across numerous carcinomas
(Table 2). The mechanism and impact on individual gene
products remains, however unclear. For some carcinomas,
theDMD gene and/or its protein products appear to be tumour
suppressive, whereas in others they appear to be oncogenic.
Dp71 in particular elicits opposing effects in gastric and lung
adenocarcinomas. These observations highlight a need to de-
termine the full complement of DMD transcripts expressed in
tumours and corresponding normal tissues. Of note, expres-
sion of the dystrophin-associated protein β-dystroglycan has
also been found to be reduced across several carcinomas, and
its function has been linked to the development and progres-
sion of prostate cancer [63–65].
7 Conclusions and perspectives
The known contribution of DMD dysregulation in the patho-
genesis across several cancers has been highlighted. There is
striking evidence for a role for DMD in most major tumour
L. Jones et al.
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The Duchenne muscular dystrophy gene and cancer
types: sarcomas, leukaemia’s/lymphomas, melanomas, carci-
nomas and nervous system cancers. However, some key ques-
tions remain. Firstly, the incidence and risk of cancer for
DMD patients is unknown, in particular whether germline
DMD inactivation may predispose to sarcoma. This will be-
come increasingly important as individuals with DMD are
living longer due to improved standards of care, and novel
treatments under development will not necessarily mitigate
against cancer risk. For example, life-lengthening treatments
that do not slow ongoing myofiber necrosis and regeneration
might increase the risk of RMS in older patients [15]. An
increased risk of cancer in myotonic dystrophy has been re-
vealed through a population-based survey [66], but to our
knowledge this has not been done for DMD patients.
Knowledge of risk may allow for individuals to receive risk
counselling. Secondly, there is little evidence across different
cancers that DMD expression and/or mutation status may
serve as independent prognostic biomarkers. Future studies
should address this question and whetherDMD acts as a driver
or passenger in tumourigenesis; the question of cause or effect
remains. The frequency of DMD gene alterations (i.e., muta-
tions and copy number alterations) varies across cancers
(Fig. 2 and [43]). In some cases, there is clear evidence of
recurrent mutations that abrogate the expression ofDMD gene
products (i.e., Dp427 in STS) and/or specific functional do-
mains such as the N-terminal actin-binding domain as seen in
meningioma [46]. Disrupted or altered gene expression
through non-mutational mechanisms may also be relevant
for disease development (i.e., virus-induced alterations in
gene expression programmes or epigenetic modifications). A
clear requirement for future work will be to identify which
DMD gene products, and isoforms thereof, are present in in-
dividual tumours. The function of Dp71d and Dp71f group
isoforms in cancer warrants particular investigation given con-
flicting data on a role in cancer cell proliferation [23, 38].
Single cell or bulk RNA next generation sequencing may be
informative in this regard, as well as the development of anti-
bodies specific for the individual gene products. We suggest
that the ratio of Dp427 to Dp71 may be important in disease
progression rather than their absolute levels (Fig. 3). The
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CNA data
Mutation data
Fig. 2 cBioportal was used to
rank DMD alteration frequencies
across the TCGA PanCancer
Atlas studies (10,953 patients
across 32 studies). Alteration
frequencies consist of mutations
(green), fusions (purple),
amplifications (red), deep
deletions (blue) and multiple al-
terations (grey). Only TCGA
studies with both mutation data
and copy number alteration
(CNA) data are shown
Fig. 3 Proposed model of
DMD-driven cancer
development. The relative
balance of the Dp427 and Dp71
gene products influences the
progression to full neoplastic
disease. Altered DMD gene
product levels have tissue-specific
effects on cancer hallmarks, such
as proliferation and invasion, and
disrupt the dystrophin-associated
protein complex (DAPC)
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tumour context may be important with gene variants acting as
either oncogenes or tumour suppressors depending on the
specific tumour microenvironment. To our knowledge a role
for DMD in intra-tumour heterogeneity has not been exam-
ined, and more work is required to ascertain the mechanisms
by which DMD dysregulation alters cancer cell functions.
Also, several cellular pathways implicated in cancer
development are disrupted in DMD. These include the
Hippo signalling pathway, which regulates apoptosis,
proliferation and tissue homeostasis. The expression of
the downstream target of the Hippo pathway, yes-
associated protein 1 (YAP), is decreased in DMD mus-
cle [67]. In the context of Duchenne, activation of YAP
is beneficial for stimulating tissue repair, whilst its in-
hibition is being pursued as an anticancer strategy [67].
Another example comes from studies on telomeres, the
maintenance of which is important in cancer. An age-
dependent telomere shortening occurs in DMD muscle,
which has been linked to cardiac failure [68–71]. This
shortening is associated with increased expression of
telomeric repeat binding factor-1 (TRF1) and poly
(ADP-ribose) polymerase-1 (PARP1), which modulate
telomere elongation [68].
Themdxmouse represents a useful in vivomodel to dissect
the contribution ofDMD to cancer development, since Dp427
expression is abolished while that of Dp71 is maintained.
However, despite numerous studies acknowledging the in-
creased, and unique, incidence of sarcomas in mdx mice, de-
tailed analysis to fully understand this phenomenon is yet to
be performed. We also advocate the development of addition-
al models such as human xenograft models to assess the con-
tribution of DMD to cancer development and the response to
therapeutic regimens.
There are exciting prospects for future combination-based
approaches that incorporate DMD-targeted therapy in cancer.
Such approaches may involve altering the ratio of different
DMD gene products, for example by restoring Dp427 expres-
sion or by reducing/abolishing the expression of Dp71. Recent
drug approvals for Duchenne utilise splice switching antisense
oligonucleotides to restore dystrophin expression in patients
[72–74]. Such innovative approaches might be repurposed for
the treatment of DMD-associated malignancies, but only
when the underpinning role of DMD in tumour development
has been fully established.
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